Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience

Abstract

Our study shows that ivabradine is likely to be effective in treating patients with POTS. Nearly 78% of our cohort reported a significant improvement in symptoms with no major adverse effects reported. A future randomized, placebo-controlled trial is warranted.